Drug intelligence / Profile preview

CQSS2

Development stage: Preclinical
Lead developer: Chrono Therapeutics
Modality: Small Molecules
Administration: Transdermal

Overview

CQSS2, also known as the Chrono Quit Smoking Solution, is a nicotine replacement therapy (NRT) system designed to aid in smoking cessation. The system delivers approximately 21 mg of nicotine over a one-day dosing period. Its primary mechanism of action is the controlled delivery of nicotine to reduce withdrawal symptoms and cravings associated with quitting smoking. The product appears to be developed for use as part of a structured quit-smoking program[7].

Other names: Chrono Quit Smoking Solution

Targets

CHRNA7 (α7 nicotinic receptor)α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)

Beyond the preview

Go deeper on CQSS2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CQSS2.

Explore the full profile